Vertex Pharmaceuticals Q1 2024 Adj EPS $4.76 Beats $4.06 Estimate, Sales $2.690B Beat $2.579B Estimate
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q1 2024 earnings of $4.76 per share, surpassing the $4.06 estimate, a 56.07% increase from last year. Sales reached $2.690B, beating the $2.579B estimate, marking a 13.26% increase from the previous year.
May 06, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex Pharmaceuticals reported a significant beat on both earnings and sales for Q1 2024, with earnings per share and sales exceeding analyst estimates.
The substantial beat on both earnings per share and sales compared to analyst estimates, coupled with significant year-over-year growth, is likely to positively impact investor sentiment and the stock price in the short term. The earnings beat by 17.24% and the sales beat by 4.31%, along with the impressive year-over-year growth in both metrics, underscore the company's strong performance and could lead to upward revisions in future earnings estimates and analyst ratings.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100